心力衰竭中胰高血糖素样肽-1受体激动剂：使用范围能扩大到何种程度？ - Suppr

GLP-1 receptor agonists in heart failure: how far to expand use?

作者信息

Hage Camilla

机构信息

Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden; Division of Cardiology, Department of Medicine, Karolinska Institutet, SE-17164 Stockholm, Sweden.

出版信息

Lancet. 2024 Sep 7;404(10456):909-911. doi: 10.1016/S0140-6736(24)01763-X. Epub 2024 Aug 30.

DOI:10.1016/S0140-6736(24)01763-X

PMID:39222643

Abstract

摘要

相似文献

GLP-1 receptor agonists in heart failure: how far to expand use?心力衰竭中胰高血糖素样肽-1受体激动剂：使用范围能扩大到何种程度？

Lancet. 2024 Sep 7;404(10456):909-911. doi: 10.1016/S0140-6736(24)01763-X. Epub 2024 Aug 30.

Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies.胰高血糖素样肽-1受体激动剂与2型糖尿病患者的心力衰竭：随机和观察性研究的系统评价与荟萃分析

BMC Cardiovasc Disord. 2016 May 11;16:91. doi: 10.1186/s12872-016-0260-0.

The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF).胰高血糖素样肽-1受体（GLP-1R）激动剂在增强内皮功能中的作用：改善射血分数保留的心力衰竭（HFpEF）的潜在途径。

Cardiovasc Diabetol. 2025 Feb 7;24(1):70. doi: 10.1186/s12933-025-02607-w.

Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.用于慢性肾病和糖尿病患者的胰高血糖素样肽1（GLP-1）受体激动剂。

Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2.

Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.药物治疗 2 型糖尿病的获益与危害：随机对照试验的系统评价和网络荟萃分析。

BMJ. 2023 Apr 6;381:e074068. doi: 10.1136/bmj-2022-074068.

Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.二肽基肽酶-4 抑制剂与胰高血糖素样肽-1 受体激动剂使用者心力衰竭住院风险的比较。

Cardiovasc Diabetol. 2018 Jul 17;17(1):102. doi: 10.1186/s12933-018-0746-4.

The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study.钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂的心血管和肾脏比较效果：斯堪的纳维亚队列研究。

Diabetes Obes Metab. 2022 Mar;24(3):473-485. doi: 10.1111/dom.14598. Epub 2021 Nov 24.

Evolving Role of Double and Triple Therapy With GLP-1 Receptor Agonists in Obesity and Cardiovascular Disease.胰高血糖素样肽-1受体激动剂双重和三联疗法在肥胖症和心血管疾病中的作用演变

Can J Cardiol. 2025 Apr 29. doi: 10.1016/j.cjca.2025.03.037.

An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors.GLP-1 受体激动剂和 SGLT-2 抑制剂心血管结局试验的更新视角和汇总分析。

Anatol J Cardiol. 2021 Feb;25(2):61-76. doi: 10.14744/AnatolJCardiol.2020.06630.

Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries.胰高血糖素样肽-1 受体激动剂在心力衰竭和 2 型糖尿病中的使用及其与结局的相关性：来自瑞典心力衰竭和瑞典国家糖尿病登记处的数据。

Eur Heart J Cardiovasc Pharmacother. 2024 Jul 16;10(4):296-306. doi: 10.1093/ehjcvp/pvae026.

引用本文的文献

Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.司美格鲁肽和替尔泊肽用于射血分数保留的心力衰竭患者

JAMA. 2025 Aug 31. doi: 10.1001/jama.2025.14092.

Refining the link between obesity and heart failure: insights from GLP-1 receptor agonist trials and studies adopting direct adiposity measures.细化肥胖与心力衰竭之间的联系：来自胰高血糖素样肽-1受体激动剂试验及采用直接肥胖测量方法的研究的见解。

Cardiovasc Diabetol. 2025 May 22;24(1):224. doi: 10.1186/s12933-025-02778-6.

Gut-Heart Axis: The Role of Gut Microbiota and Metabolites in Heart Failure.肠-心轴：肠道微生物群和代谢产物在心力衰竭中的作用。

Circ Res. 2025 May 23;136(11):1382-1406. doi: 10.1161/CIRCRESAHA.125.325516. Epub 2025 May 22.

The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction?钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）对射血分数保留的心力衰竭（HFpEF）患者心脏代谢的影响：事实还是虚构？

Cardiovasc Diabetol. 2025 May 14;24(1):208. doi: 10.1186/s12933-025-02767-9.

Heart failure and obesity: Translational approaches and therapeutic perspectives. A scientific statement of the Heart Failure Association of the ESC.心力衰竭与肥胖：转化方法与治疗前景。欧洲心脏病学会心力衰竭协会的科学声明。

Eur J Heart Fail. 2025 Jul;27(7):1273-1293. doi: 10.1002/ejhf.3676. Epub 2025 May 6.

Adoption and Prescribing Practices of Sodium-Glucose Transport Protein-2 (SGLT-2) Inhibitors and Glucagon-Like Peptide-1 (GLP-1) Agonists in Cardiology: A Cross-Sectional Study in Saudi Arabia.沙特阿拉伯钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂和胰高血糖素样肽-1（GLP-1）激动剂在心脏病学中的应用与处方实践：一项横断面研究

Cureus. 2025 Mar 15;17(3):e80610. doi: 10.7759/cureus.80610. eCollection 2025 Mar.

Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology.深入了解胰高血糖素样肽-1、二肽基肽酶-4和钠-葡萄糖协同转运蛋白2在心血管、肾脏和代谢病理生理学交叉点的作用

Cells. 2025 Mar 6;14(5):387. doi: 10.3390/cells14050387.

A Case of Severe Cholestatic Hepatitis Induced by a Novel Dual Agonist of Glucagon-like Peptide-1 and Glucose-dependent Insulinotropic Polypeptide Receptors.一例由新型胰高血糖素样肽-1和葡萄糖依赖性促胰岛素多肽受体双重激动剂引起的严重胆汁淤积性肝炎病例。

J Clin Transl Hepatol. 2024 Nov 28;12(11):949-954. doi: 10.14218/JCTH.2024.00287. Epub 2024 Oct 30.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

GLP-1 receptor agonists in heart failure: how far to expand use?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献